ClinicalTrials.gg
CompletedNCT01655693ReLiveUpdated Jun 2, 2021Results posted

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

A Phase 3 interventional study of Doxorubicin 20 mg/m2 and Doxorubicin 30 mg/m2 in Carcinoma, Hepatocellular, sponsored by Valerio Therapeutics. Completed at 70 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by Valerio Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing doxorubicin in Carcinoma, Hepatocellular — none open to participants now, 2 under way, 1 of them phase 3. Doxorubicin · Carcinoma, Hepatocellular.

Enrollment
3rd of 24
397 · median 44
Started
2012
with 2 others
Phase 3
6 of 26
none open now
Registered
19th of 26
by date

Among the 26 studies testing doxorubicin in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2012, is one of 6 in phase 3, and was the 19th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 26 studies testing doxorubicin in Carcinoma, Hepatocellular is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing doxorubicin in Carcinoma, Hepatocellular as a file.
02

Study summary

The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma (HCC) after failure or intolerance to Sorafenib. Patients with HCC with or without cirrhosis and with good liver functions are eligible. Only those who can not benefit from treatment for which efficacy is demonstrated are eligible.

These patients are usually proposed either best standard of care (BSC) or participation to clinical trials. Patients eligible for the RELIVE study will receive either DT at 20 mg/m2 or DT at 30 mg/m2 or the BSC.

Read the detailed description

Doxorubicin-Transdrug™ (DT) is a nanoparticle formulation of doxorubicin.In in vitro and in vivo models, DT was shown to overcome the multidrug resistance (MDR) and to be more effective than doxorubicin on both sensitive and resistant tumour models and in particular in the X/myc bi-transgenic MDR murine model of HCC.

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • Intermediate/advanced hepatocellular carcinoma
  • After failure or intolerance to Sorafenib.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-breast feeding female;
  • Aged ≥ 18 years;
  • Patient with:

    • advanced HCC (BCLC-C according to BCLC staging classification) having progressed under Sorafenib therapy or intolerant to Sorafenib, or;
    • intermediate HCC (BCLC-B) non eligible or non responders to transarterial chemoembolization (TACE), and having progressed under or intolerant to Sorafenib therapy
  • Patients with porta hepatis lymph nodes, extrahepatic , or portal/suprahepatic vein thrombosis without extension in inferior/superior vena cava, are eligible;
  • HCC diagnosed according to the American Association for Study of Liver Diseases (AASLD) and/or European Association for the Study of the Liver (EASL) criteria:

    • Radiological Criteria applicable in cirrhotic liver:
  • Nodule ≥ 10 mm: one imaging technique among MRI and CT-scan showing typical appearances for HCC defined as arterial enhancement and rapid washout in portal venous or delayed phase;
  • If appearance not typical for HCC on initial imaging: second contrast enhanced study (CT or MRI) showing typical appearances for HCC defined as arterial enhancement and rapid wash-out in portal venous or delayed phase;

    • And/Or cyto-histology criteria (e.g. in case of atypical lesions for HCC at imaging, absence of cirrhosis);
  • Without cirrhosis or with a non decompensated cirrhosis ( score from A5 to B7 included);
  • (ECOG) Performance Status 0 or 1;
  • Laboratory tests as follows:

    • ≥ 50,000 /mm3
    • ≥ 1000/mm3
    • ≥ 10g/dL
    • Serum transaminases \< 5 upper limit normal () (NCI/common toxicity criteria (CTC) grades 0, 1, or 2)
    • Alkaline phosphatases \< 5 ULN (NCI/CTC grades 0, 1, or 2)
    • Serum \< 35 micromolar (µM)/L (or 2.0 mg/dL);
  • Signed and dated written form.

Exclusion criteria

Exclusion Criteria:

  • Cirrhosis with a score B8-C15;
  • Untreated chronic ;
  • Patients eligible for curative treatments (transplantation, surgical resection, percutaneous treatment);
  • Patients eligible for palliative treatments with demonstrated efficacy: TACE, Sorafenib; Patients who failed to Sorafenib treatment or intolerant to sorafenib are eligible and can be included if Sorafenib has been stopped at least 2 weeks before randomization;
  • Prior history of with the exception of adequately treated basal cell carcinoma or in situ cervical cancer in complete remission since five years at least;
  • HCC developed on transplanted liver;
  • infection;
  • Risk of variceal bleeding;
  • Oxygen saturation (SaO2) \< 95%;
  • Presence of a significant acute or chronic respiratory disease defined as NCI/ > grade 2;
  • Presence of recent (\< 6 months) or current cardiac failure (class III or IV (NYHA) classification), recent (\< 6 months) acute coronary syndrome, abnormalities or recent (less than 6 months) acute vascular diseases (stroke, myocardial infarction (MI)...);
  • Prior cumulative dose of 300 mg/m² of doxorubicin or equivalent;
  • Patients currently treated with agents that cannot be stopped;
  • Patients whose medical or surgical conditions are unstable and may not allow the study completion or compliance, and specially patients with uncontrolled diabetes;
  • Uncontrolled systemic infection;
  • Patients with a of less than 2 months;
  • Patients who have received an experimental drug in another clinical trial in the last 30 days prior to randomization in the present clinical trial;
  • Women of child-bearing age who are unwilling or unable to use an effective method during the study treatment period and for 6 months after the last administration of study drug, and their male partner(s) refusing to use a condom (if applicable);
  • Men who are unwilling or unable to use a condom during the study treatment period and for 6 months after the last administration of study drug, and their female partner(s) refusing to use one of the appropriate effective contraception methods (if applicable);
  • Patients unwilling or unable to comply with protocol requirements and scheduled visits.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
397 participants (actual)

Study arms

  • Experimental
    Doxorubicin Transdrug (DT) at 20 mg/m2

    DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity

    Drug: Doxorubicin 20 mg/m2

  • Experimental
    Doxorubicin Transdrug (DT) at 30 mg/m2

    DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity

    Drug: Doxorubicin 30 mg/m2

  • Active comparator
    Best Standard of Care

    Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity

    Drug: Best Standard of Care

Interventions

  • DrugDoxorubicin 20 mg/m2

    Drug page: Doxorubicin

    Also known as: Doxorubicin Transdrug (DT) at 20 mg/m2

  • DrugDoxorubicin 30 mg/m2

    Drug page: Doxorubicin

    Also known as: Doxorubicin Transdrug (DT) at 30 mg/m2

  • DrugBest Standard of Care

    Also known as: BSC

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from date of randomization to the date of death from any cause.

    Time frame: Time from date of randomization to the date of death from any cause with initial assessment up to 24 months and follow-up assessment up to 45 months.

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as time from the date of randomisation to the date of the first documented progression or death from any cause. PFS determined by independent radiological review according to Response Evaluation Criteria In Solid Tumour (RECIST) 1.1 is determine by at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.

    Time frame: Time from date of randomization to date of first documented progression or death from any cause, which ever came first, assessed up to 20 months.

  2. Objective Response Rate (ORR)

    ORR is defined as percent of patients whose best overall response is complete response (CR) or partial response (PR) during the study treatment period and based on the evaluation of independent radiological review according to RECIST 1.1 for target lesions and assessed by MRI: CR is disappearance of all targets extra nodal lesions and the regression of all nodal lesions to \< 10 mm; PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. PD is at least a 20% increase in the sum of diameters of target lesions, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.

    Time frame: Time from date of first treatment cycle to date of last cycle of treatment for the full duration of study treatment up to 24 months.

Other outcomes

  1. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) Considered Related to Treatment Categorized by Severity, Withdrawal From Study, or Death

    The number of participants experiencing TEAEs considered related to treatment and categorized by severity of all related TEAEs according to National Cancer Institute/Common Toxicity Criteria (NCI-CTCAE) v4.0 and resulting in patient withdrawal from study or death.

    Time frame: Time from date of initial treatment to date of death, disease progression, or participant withdrawal from the study.

  2. Number of Participants With Cardiovascular and Respiratory Events Related to Study Drug

    The number of participants with cardiovascular and respiratory adverse events (AEs) were assessed according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, using the Medical Dictionary for Regulatory Activities (MedDRA). The AE numbers reported are those considered related to treatment. Related AEs are those that are judged unlikely, possibly, probably or definitely related to the study or study drug by the investigator.

    Time frame: Time from date of initial treatment to date of death, disease progression, or patient withdrawal from the study.

  3. Number of Participants Experiencing a Reduction of Oxygen Saturation (SaO2) During and After Doxorubicin Transdrug (DT) Infusion

    Number of participants experiencing an SaO2 reduction defined as a decrease =\< 90% during or after DT infusion until resolution to =\>93%. Participants had continuous monitoring of SaO2 saturation with pulse oximeter during 6 hour infusion and up to 24 hour after infusion start. SaO2 measures the amount of oxygen (in percent) bound to hemoglobin in red blood cells. SaO2 saturation was only monitored and reported in the DT infusion group. Reduction in SaO2 could result in modify DT dosing regimen. Decreases in SaO2 are a known and expected occurrence with DT infusions, and close monitoring of SaO2 was specified by the protocol to protect patients from potential respiratory distress during infusions.

    Time frame: Time from start of infusion to resolution of reduction in oxygen saturation.

  4. Number of Participants With Clinically Significant Abnormal Change in Respiratory Function

    Number of participants with any clinically significant abnormal change in respiratory function test over the study to include carbon monoxide diffusing capacity to measure lung function, forced expiratory volume in 1 second to measure ability to expel air from your lungs, total lung capacity to measure total amount of air in the lungs after taking the deepest breath possible, and vital capacity to measure the greatest volume of air that can be expelled from the lungs after taking the deepest breath possible. Clinically significant abnormal changes in respiratory function was determined by the investigator.

    Time frame: Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.

  5. Number of Participants Experiencing Clinically Significant Abnormal Electrocardiogram (ECG) Changes From Baseline

    Number of participants experiencing clinically significant abnormal ECG changes from baseline over the course of the study. ECG were completed every month before each infusion. ECG will detect changes in heart rhythm. Clinically significant abnormal changes in ECG were determined by the investigator.

    Time frame: Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.

  6. Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event

    Number of participants that experienced a change from baseline in LVEF with severity of LVEF noted as follows: Normal: 100 - 50%, 0 - 9% drop from baseline resting ejection fraction (EF), Grade 2 = 50 - 40%, 10 - 19% drop from baseline resting EF; Grade 3 = 39 - 20%, \>20% drop from baseline; Grade 4 = \<20%. LVEF was monitored every other month. LVEF measures how much blood the left ventricle of the heart pumps out with each contraction and is used to assess the severity of left ventricle dysfunction in the heart. Clinical significance changes were determined by the investigator.

    Time frame: Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.

07

Results

Posted Jun 2, 2021

Participant flow

A total of 541 patients were screened, and 397 patients were randomized a 1:1:1 allocation at 69 sites in 11 countries worldwide. The randomization was performed using an interactive web response system (IWRS) with stratification based on region. Enrollment of first patient was June 15, 2012. Data cutoff was May 28, 2017 (24 months) for initial study and May 10, 2019, for follow-up period (45 months).

Participant flow — Overall Study
MilestoneDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care
Started130133134
Completed474
Not completed126126130
Withdrew: Progression of disease927658
Withdrew: Death8912
Withdrew: Serious adverse event31511
Withdrew: Withdrawal by subject3220
Withdrew: Adverse event3113
Withdrew: Aggravation of liver dysfunction540
Withdrew: Non-compliance007
Withdrew: No respect of criteria for continuing treatment130
Withdrew: Protocol violation103
Withdrew: Lost to follow-up101
Withdrew: Screening failure100
Withdrew: Other8615

Outcome measures

PrimaryOverall Survival (OS)

OS is defined as the time from date of randomization to the date of death from any cause.

Time frame:
Time from date of randomization to the date of death from any cause with initial assessment up to 24 months and follow-up assessment up to 45 months.
Reported as:
Median · months
Overall Survival (OS)
monthsDoxorubicin Transdrug (DT) 20 mg/m2 GroupDoxorubicin Transdrug at 30 mg/m2Doxorubicin Transdrug PooledBest Standard of Care (BSC)
OS up to 24 Months10.1 (7.3 to 11.4)8.9 (7.0 to 10.3)9.1 (8.1 to 10.4)9.0 (7.1 to 11.8)
OS up to 45 Months9.8 (7.4 to 11.2)8.8 (7.1 to 10.3)8.9 (8.1 to 10.3)9.0 (7.2 to 11.8)
Statistical analysis
  • Doxorubicin Transdrug (DT) 20 mg/m2 Group vs Doxorubicin Transdrug at 30 mg/m2 vs Doxorubicin Transdrug Pooled vs Best Standard of Care (BSC) · Log Rank · p = >0.991 (Treatment comparison of DT pooled with BCS used non-stratified Log-rank test at significance level p=0.05.) · Hazard ratio (hr): 1.00The hazard ratio was controlled for the overall type I error rate at 5% (2-sided) corresponding to 95% confidence interval (CI) and type II error rate as 15%.
  • Doxorubicin Transdrug (DT) 20 mg/m2 Group vs Doxorubicin Transdrug at 30 mg/m2 vs Doxorubicin Transdrug Pooled vs Best Standard of Care (BSC) · Log Rank · p = 0.796 (Treatment comparison of DT pooled with BCS used non-stratified Log-rank test at significance level p=0.05.) · Hazard ratio (hr): 1.00The hazard ratio was controlled for the overall type I error rate at 5% (2-sided) corresponding to 95% confidence interval (CI) and type II error rate as 15%.
SecondaryProgression-free Survival (PFS)

PFS is defined as time from the date of randomisation to the date of the first documented progression or death from any cause. PFS determined by independent radiological review according to Response Evaluation Criteria In Solid Tumour (RECIST) 1.1 is determine by at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.

Time frame:
Time from date of randomization to date of first documented progression or death from any cause, which ever came first, assessed up to 20 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Doxorubicin Transdrug PooledBest Standard of Care
Progression-free Survival (PFS)2.3 (2.0 to 2.8)2.3 (2.1 to 2.6)2.3 (2.1 to 2.6)2.3 (2.1 to 2.8)
Statistical analysis
  • Doxorubicin Transdrug (DT) at 20 mg/m2 vs Doxorubicin Transdrug at 30 mg/m2 vs Best Standard of Care · Log Rank · p = 0.7 (Treatment comparison with BCS using non-stratified Log-rank test at significance level p=0.05.) · Hazard ratio (hr): 1.00Hazard ratio for treatment variable was determined by Cox model. The hazard ratio was controlled for the overall type I error rate at 5% (2-sided) and type II error rate as 15%.
SecondaryObjective Response Rate (ORR)

ORR is defined as percent of patients whose best overall response is complete response (CR) or partial response (PR) during the study treatment period and based on the evaluation of independent radiological review according to RECIST 1.1 for target lesions and assessed by MRI: CR is disappearance of all targets extra nodal lesions and the regression of all nodal lesions to \< 10 mm; PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of diameters while on study. PD is at least a 20% increase in the sum of diameters of target lesions, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is considered progression.

Time frame:
Time from date of first treatment cycle to date of last cycle of treatment for the full duration of study treatment up to 24 months.
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Doxorubicin Transdrug PooledBest Standard of Care
Complete Response0000
Partial Response0221
Stable Disease39418031
Progressive Disease586312140
Not Evaluable33276062
Statistical analysis
  • Doxorubicin Transdrug (DT) at 20 mg/m2 vs Doxorubicin Transdrug at 30 mg/m2 vs Doxorubicin Transdrug Pooled vs Best Standard of Care · Fisher Exact · p = 1.0 (Treatment comparison with BCS using Fisher's exact test at significance level p=0.05.)
Other pre-specifiedNumber of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) Considered Related to Treatment Categorized by Severity, Withdrawal From Study, or Death

The number of participants experiencing TEAEs considered related to treatment and categorized by severity of all related TEAEs according to National Cancer Institute/Common Toxicity Criteria (NCI-CTCAE) v4.0 and resulting in patient withdrawal from study or death.

Time frame:
Time from date of initial treatment to date of death, disease progression, or participant withdrawal from the study.
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) Considered Related to Treatment Categorized by Severity, Withdrawal From Study, or Death
ParticipantsDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care (BSC)
TEAEs799858
Severe TEAEs264631
Serious TEAEs131813
TEAEs Leading to Withdrawal599
TEAEs Leading to Death121
Other pre-specifiedNumber of Participants With Cardiovascular and Respiratory Events Related to Study Drug

The number of participants with cardiovascular and respiratory adverse events (AEs) were assessed according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0, using the Medical Dictionary for Regulatory Activities (MedDRA). The AE numbers reported are those considered related to treatment. Related AEs are those that are judged unlikely, possibly, probably or definitely related to the study or study drug by the investigator.

Time frame:
Time from date of initial treatment to date of death, disease progression, or patient withdrawal from the study.
Reported as:
Count of participants · Participants
Number of Participants With Cardiovascular and Respiratory Events Related to Study Drug
ParticipantsDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care (BSC)
Cardiac Disorders451
Vascular Disorders886
Blood Pressure Increased010
Respiratory, Thoracic, and Mediastinal Disorders172013
Oxygen Saturation Decreased271
Respiratory Rate Increased250
Respiratory Rate Decreased110
Ejection Fraction Decreased100
Other pre-specifiedNumber of Participants Experiencing a Reduction of Oxygen Saturation (SaO2) During and After Doxorubicin Transdrug (DT) Infusion

Number of participants experiencing an SaO2 reduction defined as a decrease =\< 90% during or after DT infusion until resolution to =\>93%. Participants had continuous monitoring of SaO2 saturation with pulse oximeter during 6 hour infusion and up to 24 hour after infusion start. SaO2 measures the amount of oxygen (in percent) bound to hemoglobin in red blood cells. SaO2 saturation was only monitored and reported in the DT infusion group. Reduction in SaO2 could result in modify DT dosing regimen. Decreases in SaO2 are a known and expected occurrence with DT infusions, and close monitoring of SaO2 was specified by the protocol to protect patients from potential respiratory distress during infusions.

Time frame:
Time from start of infusion to resolution of reduction in oxygen saturation.
Reported as:
Count of participants · Participants
Number of Participants Experiencing a Reduction of Oxygen Saturation (SaO2) During and After Doxorubicin Transdrug (DT) Infusion
ParticipantsDoxorubicin Transdrug (DT) 20 mg/m2Doxorubicin Transdrug 30 mg/m2
Number of Participants Experiencing a Reduction of Oxygen Saturation (SaO2) During and After Doxorubicin Transdrug (DT) Infusion24
Other pre-specifiedNumber of Participants With Clinically Significant Abnormal Change in Respiratory Function

Number of participants with any clinically significant abnormal change in respiratory function test over the study to include carbon monoxide diffusing capacity to measure lung function, forced expiratory volume in 1 second to measure ability to expel air from your lungs, total lung capacity to measure total amount of air in the lungs after taking the deepest breath possible, and vital capacity to measure the greatest volume of air that can be expelled from the lungs after taking the deepest breath possible. Clinically significant abnormal changes in respiratory function was determined by the investigator.

Time frame:
Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Change in Respiratory Function
ParticipantsDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care (BSC)
Number of Participants With Clinically Significant Abnormal Change in Respiratory Function1380
Other pre-specifiedNumber of Participants Experiencing Clinically Significant Abnormal Electrocardiogram (ECG) Changes From Baseline

Number of participants experiencing clinically significant abnormal ECG changes from baseline over the course of the study. ECG were completed every month before each infusion. ECG will detect changes in heart rhythm. Clinically significant abnormal changes in ECG were determined by the investigator.

Time frame:
Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.
Reported as:
Count of participants · Participants
Number of Participants Experiencing Clinically Significant Abnormal Electrocardiogram (ECG) Changes From Baseline
ParticipantsDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care (BSC)
Number of Participants Experiencing Clinically Significant Abnormal Electrocardiogram (ECG) Changes From Baseline465
Other pre-specifiedNumber of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event

Number of participants that experienced a change from baseline in LVEF with severity of LVEF noted as follows: Normal: 100 - 50%, 0 - 9% drop from baseline resting ejection fraction (EF), Grade 2 = 50 - 40%, 10 - 19% drop from baseline resting EF; Grade 3 = 39 - 20%, \>20% drop from baseline; Grade 4 = \<20%. LVEF was monitored every other month. LVEF measures how much blood the left ventricle of the heart pumps out with each contraction and is used to assess the severity of left ventricle dysfunction in the heart. Clinical significance changes were determined by the investigator.

Time frame:
Time from baseline assessment to time of death, disease progression, or withdrawal of patient from the study.
Reported as:
Count of participants · Participants
Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event
ParticipantsDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care (BSC)
At Least One Abnormal Value142
At Least One Grade 3-4 Value111

Adverse events

Collected over Adverse events (AEs) were collected until 1 month after last treatment. Treatment continued until patient experienced disease progression, aggravation of liver dysfunction, death, serious AE (SAE), or intolerable AE; or the patient withdrew consent or was withdrawn from study by investigator for reasons listed in the protocol. Median treatment durations were 1.9, 2.7, and 2.4 months in the Doxorubicin Transdrug (DT) 20 mg/m2, DT 30 mg/m2, and best standard of care (BSC) groups, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxorubicin Transdrug (DT) at 20 mg/m2118/122 (96.7%)37/122 (30.3%)110/122 (90.2%)
Doxorubicin Transdrug at 30 mg/m2119/120 (99.2%)37/120 (30.8%)112/120 (93.3%)
Best Standard of Care113/134 (84.3%)48/134 (35.8%)97/134 (72.4%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care
General physical health deteriorationGeneral disorders3/1222/1208/134
Hepatic encephalopathyHepatobiliary disorders1/1225/1207/134
Oesophageal varices haemorrhageGastrointestinal disorders1/1223/1207/134
AnaemiaBlood and lymphatic system disorders1/1221/1204/134
FatigueGeneral disorders0/1223/1200/134
Catheter site infectionInfections and infestations3/1220/1202/134
AscitesGastrointestinal disorders3/1221/1203/134
Abdominal painGastrointestinal disorders3/1220/1201/134
DysphagiaGastrointestinal disorders3/1220/1201/134
Acute kidney injuryRenal and urinary disorders0/1220/1203/134
Most frequent other events
Showing 10 of 39
Most frequent other events
EventDoxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of Care
AstheniaGeneral disorders41/12257/12039/134
NauseaGastrointestinal disorders26/12233/12024/134
Oedema peripheralGeneral disorders9/12225/12024/134
PyrexiaGeneral disorders9/12223/1208/134
DiarrhoeaGastrointestinal disorders21/12223/12020/134
AnaemiaBlood and lymphatic system disorders15/12222/12022/134
ThrombocytopeniaBlood and lymphatic system disorders2/12214/12024/134
VomitingGastrointestinal disorders15/12220/12010/134
Decreased AppetiteMetabolism and nutrition disorders16/12219/12021/134
NeutropeniaBlood and lymphatic system disorders4/12218/1207/134

Baseline characteristics

Intent-to-Treat population: all randomized patients.

Age, Categorical
Age, Categorical(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
<=18 years0000
Between 18 and 65 years506257169
>=65 years807177228
Sex: Female, Male
Sex: Female, Male(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
Female12271857
Male118106116340
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
White120119125364
Black1326
Asian1326
Other1337
Hispanic or Latino0213
Native Hawaiian or Other Pacific Islander0000
North African6208
American Indian or Alaska Native0000
Unknown1113
Region of Enrollment
Region of Enrollment(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
United States2237
Europe118120119357
Middle East10111233
Alcohol Consumption
Alcohol Consumption(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
No Significant Alcohol Consumption119127123369
Active Alcohol Consumption1161128
Child Pugh Class
Child Pugh Class(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
Child Pugh A114109113336
Child Pugh B15242160
Child Pugh C1001
Previous Hepatocellular Carcinoma (HCC) Treatments
Previous Hepatocellular Carcinoma (HCC) Treatments(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
Surgery/Resection414940130
Loco-regional Treatment848484252
Radiotherapy1414937
Sorafenib130133134397
Other Systemic Anticancer Therapy687380221
Medical History Active
Medical History Active(Participants)Doxorubicin Transdrug (DT) at 20 mg/m2Doxorubicin Transdrug at 30 mg/m2Best Standard of CareTotal
Hypertension738284239
Type 2 Diabetes Mellitus28153578
Diabetes Mellitus17261760
Hypercholestrolaemia1214935
Varices Oesophageal14241553
Chronic Obstructive Pulmonary Disease138930
Thrombocytopenia715830

8 further baseline measures are reported on the registry.

08

Study locations

70 sites
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Penn State Hershey Cancer Institute
    Hershey, Pennsylvania 17033, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Krankenhaus der Elisabethinen Linz GmbH
    Linz, 4020, Austria
  • Medical University Vienna
    Vienna, 1090, Austria
  • CHU Brugmann
    Brussels, 1020, Belgium
  • UCL Saint-Luc
    Brussels, 1200, Belgium
  • CHU Sart Tilman
    Liège, 4000, Belgium
  • CHU UCL Mont-Godinne Dinant
    Yvoir, Belgium
  • Clinical Research Center/ Alexandria university hospital
    Alexandria, Egypt
  • Oncology Department, Medical Research Institute, Alexandria University
    Alexandria, Egypt
  • Medical Oncology department /Ain Shams University Hospitals
    Cairo, Egypt
  • National hepatology and tropical medicine research institute
    Cairo, Egypt
  • Medical Oncology department /Mansoura University Hospitals
    Mansoura, 35516, Egypt
  • National Liver Institute / Menoufyia University
    Menofia, 32700, Egypt
  • Hospital Amiens
    Amiens, 80054, France
  • Hospital Jean Minjoz
    Besançon, 25000, France
  • Hospital Saint André
    Bordeaux, 33075, France
  • Centre hospitalier P Oudot
    Bourgoin-Jallieu, 38302, France
  • Hospital Estaing
    Clermont-Ferrand, 63003, France
  • Centre Hospitalier Beaujon
    Clichy, 92110, France
  • Hospital Henri-Mondor
    Creteil, 94010, France
  • Centre Jean-François Leclerc
    Dijon, 21079, France
  • CHU
    Dijon, France
  • Hospital Grenoble
    La Tronche, 38700, France
  • CHU Dupuytren
    Limoges, 87042, France
  • Hospital Croix Rousse
    Lyon, 69317, France
  • Hospital La Timone
    Marseille, 13005, France
  • Hospital Saint Eloi
    Montpellier, 34295, France
  • Hospital Brabois
    Nancy, 54511, France
  • Hospital Hotel Dieu
    Nantes, 44093, France
  • CHU - Hôpital Archet
    Nice, France
  • Hospital La Source
    Orleans, 45067, France
  • Hospital Pitié-Salpetriere
    Paris, 75013, France
  • Hospital Tenon
    Paris, 75020, France
  • Hospital Saint Jean
    Perpignan, 66046, France
  • CHU de Rouen- Hôpital Charles Nicolle
    Rouen, 76031, France
  • IC LOIRE
    Saint-Etienne, France
  • Hospital Civil
    Strasbourg, 67091, France
  • Hospital Paul Brousse
    Villejuif, 94804, France
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Universitätsklinikum Halle (Saale)
    Halle An Der Saale, 06120, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universität Leipzig AöR
    Leipzig, 04103, Germany
  • Klinikum rechts der Isar der TU Munchen II
    Munchen, 81675, Germany
  • Semmelweis Egyetem Radiológiai és Onkoterápiás Klinika
    Budapest, 1082, Hungary
  • Egyesített Szent István és Szent László Kórház - Rendelőintézet
    Budapest, 1097, Hungary
  • Debreceni Egyetem Orvos- és Egészségtudományi Centrum Onkológiai Intézet
    Debrecen, 4032, Hungary
  • Szegedi Tudományegyetem Onkoterápiás Klinika
    Szeged, 6720, Hungary
  • Irccs Centro Di Riferimento Oncologico (Cro)
    Aviano, 33081, Italy
  • Ospedale Civile e degli Infermi
    Faenza, 48018, Italy
  • Ausl 12 Livorno Ospedale Unico della Versilia
    Lido di Camaiore, 55041, Italy
  • IRST Istituto Romagnolo Ricerca e Cura dei Tumori
    Meldola, 47014, Italy
  • Granda Osp. Magg. Policlinico
    Milano, 20122, Italy
  • Azienda Ospedaliera Policlinico di Modena
    Modena, 41124, Italy
  • A.O. Ospedale Maggiore della Carità
    Novara, 28100, Italy
  • Rimini, 47900, Italy
  • Ain Wazein Hospital
    El Chouf, Lebanon
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital Universitario Virgen de la Arrixaca
    El Palmar Murcia, 30120, Spain
  • Complejo Hospitalario de Jaen
    Jaen, 23006, Spain
  • Hospital General Universario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
  • Hospital Carlos Haya
    Malaga, 29010, Spain
  • Hospital Universario Son Espaces
    Palma De Mallorca, 07010, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital Universitario Río Hortega
    Valladolid, 47012, Spain
  • Hacettepe University Medical Faculty
    Ankara, Turkey
  • Ege Univeristy Medical Faculty,
    İzmir, Turkey
09

References and documents

Publications

  • Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Mole A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Erratum In: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e6. doi: 10.1016/S2468-1253(19)30152-9. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):e1. doi: 10.1016/S2468-1253(19)30424-8. PubMed 30954567 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in May 2017, 59 months.

Results were first posted in Jun 2021, 4 years 1 month after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 59 months is above that.

Counting every sponsor, half of 138 studies reached it within 56 months; a quarter within 43 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2012
First posted
Aug 2, 2012
StartActual
Jun 2012
Primary completionActual
May 2017
CompletionActual
May 2019
Results first posted
Jun 2, 2021
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01655693
Responsible party
Sponsor
First posted
Aug 2, 2012
Start date
Jun 2012
Primary completion
May 2017
Completion
May 2019
Results posted
Jun 2, 2021
Last update
Jun 2, 2021

Study contacts

Philippe Merle, MD
principal investigator · Croix-Rousse Hospital - Lyon-France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion